股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2026年1月31日 | | --- | | 狀態: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 优趣汇控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02177 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 165,894,700 0 165,894,700 增加 / 減少 (-) 0 0 本月底結存 165,894,700 0 165,894,700 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） | | 未符合適用的公眾持股量要求（見下方） | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 优趣汇控股有限公司 呈交日期: 2026年1月6日 本月底法定/註冊股本總額： HKD 380,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02177 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 165,894,700 | | 0 | | 165,894,700 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 165,894,700 | | 0 | | 165,894, ...

Core Viewpoint - The acquisition of 90% stake in One Two Co., Ltd. by Youquhui Holdings for 2.701 billion yen (approximately 135 million HKD) marks a strategic move to establish a second growth curve for the company, enhancing its influence in the health consumption sector and integrating online and offline retail ecosystems [1][2][5]. Group 1: Acquisition Details - Youquhui has completed the acquisition of 90% of One Two Co., Ltd., which operates the Japanese pharmacy chain "あかひげ薬局" [1]. - The acquisition cost was 2.701 billion yen (approximately 135 million HKD), and the brand name and core team of あかひげ薬局 will be retained post-acquisition [1]. - あかひげ薬局 focuses on health management for middle-aged and elderly men, providing personalized health solutions through a one-on-one consultation model [3]. Group 2: Strategic Significance - The acquisition strengthens Youquhui's position in the high-potential health consumption market and provides access to a rare localized overseas brand [2]. - Youquhui aims to leverage the established retail network and expertise of あかひげ薬局 to transition from online operations to a hybrid online and offline retail ecosystem [2][4]. - The integration of Youquhui's digital capabilities with あかひげ薬局's professional services is expected to enhance operational efficiency and market reach [4]. Group 3: Growth Strategy - Youquhui has been actively building its second growth curve, previously launching the Canadian anti-aging health food brand Vanpearl and recruiting international experts to bolster its talent pool [6][7]. - The acquisition of あかひげ薬局 is seen as a natural extension of Youquhui's long-term strategy, enhancing its capabilities in research, brand management, and service delivery [7]. - The company is positioned to potentially engage in further acquisitions in the health consumption sector to strengthen its comprehensive capabilities across research, branding, and multi-channel operations [7][8].

Core Viewpoint - The acquisition of 90% stake in One Two Co., Ltd. by Youquhui Holdings for 2.701 billion yen (approximately 135 million HKD) marks a strategic move to establish a second growth curve for the company, enhancing its influence in the health consumption sector and integrating online and offline retail ecosystems [1][2][5]. Group 1: Acquisition Details - Youquhui has completed the acquisition of 90% of One Two Co., Ltd., which operates the Japanese pharmacy chain "あかひげ薬局" [1]. - The acquisition cost was 2.701 billion yen (approximately 135 million HKD), and the brand name and core team of あかひげ薬局 will be retained post-acquisition [1]. - あかひげ薬局 focuses on health management for middle-aged and elderly men, providing personalized health solutions through a one-on-one consultation model [3]. Group 2: Strategic Significance - The acquisition strengthens Youquhui's position in the high-potential health consumption market and provides access to a rare localized overseas brand [2]. - Youquhui aims to leverage the established retail network and expertise of あかひげ薬局 to transition from online operations to a hybrid online and offline retail model [2][4]. - The collaboration is expected to shorten the incubation period for developing proprietary brands and enhance competitive growth [2]. Group 3: Operational Synergies - Youquhui's extensive experience in the Japanese market and its established operational systems will facilitate the integration of あかひげ薬局 into its business model [4]. - The company plans to innovate service models, expand regional markets, and upgrade technology in collaboration with あかひげ薬局 [4]. - The focus will be on creating a comprehensive ecosystem that combines professional pharmaceutical services with intelligent health management across multiple markets in Asia [4]. Group 4: Growth Trajectory - Youquhui has been actively building its second growth curve, previously launching the Canadian anti-aging health food brand Vanpearl [6][7]. - The acquisition of あかひげ薬局 complements the establishment of a proprietary brand and enhances Youquhui's capabilities in research, brand management, and multi-channel operations [7]. - The company is expected to pursue further acquisitions in the health consumption sector to strengthen its full-chain capabilities [7][8]. Group 5: Market Positioning - The strategic moves by Youquhui are aligned with current market trends, positioning the company favorably amidst a slowing economic environment [8]. - The establishment of a new growth engine beyond its traditional business is anticipated to enhance the company's long-term investment value [8].

优趣汇控股(02177)发布公告，有关收购One Two Co., Ltd.*(株式会社ワン ツー)，一家于日本注册成立 的有限公司的约90%已发行股份。SPA所订明的所有条件均已达成，且完成已于2026年1月5日发生。于 完成后，目标公司成为公司间接非全资附属公司，其财务业绩已于集团的财务报表综合入账。 ...

格隆汇1月5日丨优趣汇控股(02177.HK)公告，内容有关收购One Two Co., Ltd.*(株式会社ワン•ツー)，一 家于日本注册成立的有限公司之约90%已发行股份。董事会欣然宣布，SPA所订明之所有条件均已达 成，且完成已于2026年1月5日发生。于完成后，One Two Co., Ltd.*(株式会社ワン•ツー)成为公司间接非 全资附属公司，其财务业绩已于集团的财务报表综合入账。 ...

智通财经APP讯，优趣汇控股(02177)发布公告，有关收购One Two Co., Ltd.*(株式会社ワン • ツー)，一 家于日本注册成立的有限公司的约90%已发行股份。SPA所订明的所有条件均已达成，且完成已于2026 年1月5日发生。于完成后，目标公司成为公司间接非全资附属公司，其财务业绩已于集团的财务报表综 合入账。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 會 就 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 董 事 會 欣 然 宣 佈，SPA所 訂 明 之 所 有 條 件 均 已 達 成，且 完 成 已 於2026年1月5日 發 生。 於 完 成 後，目 標 公 司 成 為 本 公 司 間 接 非 全 資 附 屬 公 司，其 財 務 業 績 已 於 本 集 團 的 財 務 報 表 綜 合 入 賬。 * 僅供識別 承董事會命 优 趣 匯 控股有限公司 王 勇 UNQ HOLDINGS LIMITED 優趣匯控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2177） 完成有關收購一家日本公司股份之須予披露交易 茲提述优趣 匯 控股有限公司（「本公司」）日期為2025年12月15日之公告（「該 公 告」），內 容 有 關 收 購One Two Co., Ltd.*（株 式 會 社ワン • ツー），一 家 於 日 本 ...

UNQ HOLDINGS LIMITED 優趣匯控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 （股 份 代 號：2177） 於2025年12月24日舉行之股東特別大會之投票表決結果 优 趣 匯 控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈於2025年12月24日 （星 期 三）上午十時正假座中國上海市浦東新區浦明路1436號陸家嘴濱江中心 MT座503室舉行的股東特別大會（「股東特別大會」）的 投 票 表 決 結 果。 董 事 王 勇 先 生、沈 宇 先 生、陳 偉 偉 女 士、中 山 國 慶 先 生、吳 錦 華 博 士、魏 航 先 生 及 辛 洪 華 女 士 親 自 或 以 電 子 方 式 出 席 股 東 特 別 大 會。 本公司的香港股份登記及過戶分處香港中央證券登記有限公司擔任股東特別 大 會 點 票 的 ...

New IPOs - Guoxia Technology (02655) received a subscription rate of 1890.73 times for its public offering in Hong Kong, with a share price of HKD 20.1 [1] - Easy Health (02661), Hansai Aitai-B (03378), and Nobi Kan (02635) are scheduled for public offerings from December 15 to December 18, with expected listing on December 23 [1] Major Events - Luoyang Molybdenum (03993) plans to acquire three major gold mining assets in Brazil for USD 1.015 billion [1] - Zhongwei New Materials (02579) has been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect securities list [1] - Botai Carlink (02889) received a first project confirmation notice from a leading domestic new energy vehicle client [1] - Xiehe New Energy (00182) intends to sell 100% equity of Cangzhou Julong for CNY 65.3 million [1] - Fosun Pharma (02196) plans to invest a total of CNY 1.412 billion to gain control of Green Valley Pharmaceutical [1] - Youqu Holdings (02177) intends to spend JPY 2.701 billion to acquire the Japanese consulting pharmacy chain Akahige [1] Financial Data - China Metallurgical Group (01618) signed new contracts worth CNY 958.13 billion in the first 11 months, a decrease of 8.6% year-on-year [1] - Xinhua Insurance (01336) reported a cumulative original insurance premium income of CNY 188.85 billion in the first 11 months, an increase of 16% year-on-year [1] - China Southern Airlines (01055) saw a 10.42% year-on-year increase in passenger turnover in November [1] - China Shenhua (01088) reported coal sales of 389.5 million tons in the first 11 months, a decrease of 7.7% year-on-year [1] - China Eastern Airlines (00670) experienced a 10.35% year-on-year increase in passenger turnover in November [1] - Air China (00753) reported a 10.1% year-on-year increase in passenger turnover in November [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.051 million shares for HKD 636 million on December 15 [2] - Xiaomi Group-W (01810) repurchased 7.2 million shares for HKD 302 million on December 15 [2] - Geely Automobile (00175) repurchased 1.991 million shares for HKD 34.7485 million on December 15 [2] - Kuaishou-W (01024) repurchased 462,000 shares for HKD 29.9304 million on December 15 [2] - Rongchang Bio (09995) plans to repurchase shares worth between CNY 2 million and CNY 4 million [2] - Gendyn New Drug (01952) received over HKD 38 million in share purchases from directors and major shareholders [2]